Taking a break from the harsh closed loops and hunkering down in dis stone chamber to give a little freestyle riff for this episode from the stone chamber
no links 
except go watch the video. the audio just won't cut it on this one
https://youtu.be/bEIqg2lcDU0

Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

I bust through the third wall or whatevs in Episode 10 of TSC Talks 3.0 Research. Dropped the whiteboard til the end. Summed up the 9 episodes and added a bit on the end about CPTSD, TAND and the fact that the entire family system is drawn into the grid as data churnin' emotin' node. Used the Google AI to investigate the theories I had on amplification of TSC by multiple factors for purpose and product and it proved true based on the research plus lived experience thus far.

Source Links for Further Research
I. Rare Disease Advocacy and Funding (Conflicts of Interest)
[TSC Alliance: Corporate Policies](https://www.tscalliance.org/about-tsc/corporate-policies/)
[TSC Alliance: COVID-19 Vaccine Position Statement](https://www.tscalliance.org/wp-content/uploads/2021/08/TSC-Alliance-COVID-19-Vaccine-Position-Statement-Update-August-2021-FINAL.pdf)
[TSC Alliance: Phenotypic Variability Research](https://www.tscalliance.org/tsc-matters/phenotypic-variability-in-tuberous-sclerosis-complex-tsc/)
[TSC Alliance: 2024 Talking Points](https://www.tscalliance.org/wp-content/uploads/2024/01/2024-Talking-Points-Final.pdf)
[NORD: Mission and Values](https://rarediseases.org/about-us/mission-values/)
[NORD: Research Grant Programs](https://rarediseases.org/advancing-research/research-grant-programs/) 
[EURORDIS: Our Funding](https://www.eurordis.org/who-we-are/our-funding/)
[Mass General: Herscot $50 Million Gift](https://giving.massgeneral.org/stories/herscots-make-50-million-gift-to-mass-general)
[NEJM: Industry Support for Patient Advocacy](https://www.nejm.org/doi/full/10.1056/NEJMsr1610625)
II. Gene Therapy (CRISPR), Risks, and Regulation 
[FDA: Cellular & Gene Therapy Products](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products)
[CRISPR-Cas9 Off-Target Effects (Synthego)](https://www.synthego.com/blog/crispr-off-target-editing/)
[CRISPR: Genome Engineering Advantages and Limitations (Taconic)](https://www.taconic.com/resources/crispr-genome-engineering-advantages-limitations)
[FDA: Regulatory Distinctions for Cell and Gene Therapies (LinkedIn)](https://www.linkedin.com/pulse/fda-vs-ema-key-regulatory-distinctions-cell-gene-therapies-ywzye) [Informed Consent and Clinical Trials (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2659702/) [Immune Evasion in Engineered CRISPR Enzymes (Broad Institute)](https://www.broadinstitute.org/news/scientists-engineer-crispr-enzymes-evade-immune-system) [The Ethics of Gene Editing (Innovative Genomics)](https://innovativegenomics.org/crisprpedia/crispr-ethics/)
III. Vaccines, Toxins, and Environmental Amplification 
[TSC Drug Market & Prevalence (OpenPR)](https://www.openpr.com/news/3536609/tuberous-sclerosis-complex-drug-market-2034-epidemiology)
[Vaccines and the Rise in Pediatric Cancer (The Vaccine Reaction)](https://thevaccinereaction.org/2018/05/is-there-a-link-between-vaccines-and-the-rise-in-pediatric-cancer/) 
[Study of Vaccinated and Unvaccinated Children (Weston A. Price)](https://www.westonaprice.org/health-topics/vaccinations/chronic-disease-a-study-of-vaccinated-and-unvaccinated-children/#gsc.tab=0)
[Role of Environmental Toxins in Epigenetic Dysregulation (PLM Institute)](https://plminstitute.org/plmi-blog/the-role-of-environmental-toxins-in-epigenetic-dysregulation/) [Childhood Vaccination Schedule Explosion (Twitter - NVICLoeDown)](https://twitter.com/NVICLoeDown/status/1687176816774033408) [COVID-19 Vaccine Added to Childhood Schedule (Children's Health Defense)](https://childrenshealthdefense.org/defender/childhood-covid-vaccine-schedule/) [The Role of Environmental Exposures in Genetic Disease (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4021822/)
IV. Alternative and Holistic Approaches
[Ketogenic Diet Inhibits the mTOR Pathway (AESnet)](https://aesnet.org/abstractslisting/the-ketogenic-diet-inhibits-the-mammalian-target-of-rapamycin-\(mtor\)-pathway)
[Ketogenic Diet for Epilepsy in TSC (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5540690/) [Curcumin Inhibits mTOR Activity (ScienceDirect)](https://www.sciencedirect.com/science/article/abs/pii/S0944711318304860)
[Natural Treatment for TSC (Inspire Forum)](https://www.inspire.com/groups/tuberous-sclerosis-complex/discussion/natural-treatment-for-tsc/)
[Natural Products and Patenting (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8521639/) [Anti-Inflammatory Living (Holistic Health Code)](https://www.holistichealthcode.com/articles/unlocking-metabolic-health)
contact Jill: [email protected]

Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

In this episode, I get into mitigation strategies related to the increasing reliance on tech with the arrival of 6G particularly for those living with a chronic and or rare disease that is on multiple medications and dependent on the grid. What would be considered alternative or holistic therapies such as grounding, sound therapy, ketogenic diet and exercise have all been proven to help support the full field in finding homeostasis even with a condition such as TSC and can improve overall health and quality of life as a support beyond meds and other more drastic regimens. I also talk about the similarities between CPTSD and TAND (TSC Associated Neuropsychiatric Disorder) and the importance of understanding the "energetics" of a rare disease when advocating for one's self and/or loved ones. The system will add additional labels and complicate understanding. I hope to explore further the CPTSD connection as I feel it as AS relevant as the limited focus of TAND.

Full list of links: https://docs.google.com/document/d/e/2PACX-1vQv_yBMqtFvxQmhm31TXozv20_nEGxCTwjUCclYrEK2yE9NGR6rQqc1GyMsA76lUNtNrZda-FF_Z2IM/pub


Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

Episode 8 of TSC Talks 3.0 Research... continuing on with the extensive history of the rare disease Tuberous Sclerosis Complex, the set up for data harvesting and gene editing and the inevitability of enhanced grid adhesion. Woohoo! Next episode I'm gonna go into mitigation and the upswing of the sitch. 
Links:
mindandbodyexercises.com
https://medium.com
https://maescenter.com
rockarch.org
tikvahhealthandwellness.com
nih.gov
nih.gov
nutritiondiagnostics.com.au
nih.gov
psychologytoday.com
nih.gov
mcgill.ca
chop.edu
https://historyofvaccines.org
nih.gov
jpeds.com
https://time.com
nih.gov
nih.gov
nih.gov
2minutemedicine.com
nih.gov
nih.gov
sciencedirect.com
nih.gov
cdc.gov
nih.gov
https://richd.org
nih.gov
wikipedia.org
empr.com
https://historyofvaccines.org
https://drgreenmom.com
mayoclinic.org
kaiserpermanente.org
nih.gov
kff.org
forbes.com
itu.int
ciocoverage.com
https://studyfinds.org

Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

The history of Tuberous Sclerosis Complex.
they're juicing it.
Some queries related to the complexity of epigenetic variables and the overlords decision to focus on genetics only for the sake of "simplicity"...
Just my opinion?
I welcome all listeners and critical thinkers.
📚 Primary Research & Databases PubMed Central (Full-Text Archive): https://pmc.ncbi.nlm.nih.gov
PubMed (Citations & Abstracts): https://pubmed.ncbi.nlm.nih.gov
ScienceDirect: sciencedirect.com
Wiley Online Library: https://onlinelibrary.wiley.com
Springer Link: https://link.springer.com
ResearchGate: researchgate.net Academia.edu: academia.edu
🏥 Health Organizations & Agencies NIH / National Library of Medicine: https://www.ncbi.nlm.nih.gov
NINDS (Neurological Disorders): https://www.ninds.nih.gov
MedlinePlus: https://medlineplus.gov
HRSA (Health Resources): hrsa.gov
Texas Children’s Hospital: texaschildrens.org
TSC Alliance: tscalliance.org
Epilepsy Foundation: epilepsy.com
🔬 Specialized Medical Journals
The Lancet: thelancet.com Pediatric Neurology: pedneur.com
Neurotherapeutics: neurotherapeuticsjournal.org
Frontiers in Science: frontiersin.org eLife Sciences: https://elifesciences.org
AMA Journal of Ethics: ama-assn.org
AAP Publications: aap.org ACR Journals: https://acrjournals.onlinelibrary.wiley.com
ACR Abstracts: https://acrabstracts.org
2 Minute Medicine: https://www.2minutemedicine.com
📰 News, Legal & Historical Context
TIME Magazine: https://time.com
Medical Xpress: https://medicalxpress.com
History of Vaccines: https://historyofvaccines.org
Texas Vaccine Lawyers: texasvaccinelawyers.com
Digital Commons (Rockefeller): rockefeller.edu HealthCentral: healthcentral.com Changing Aging: https://changingaging.org
Medium: https://medium.com
Meridian Health Clinic: https://meridianhealthclinic.com
Wikipedia: wikipedia.org WikiDoc: wikidoc.org
contact Jill ~ [email protected]

Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

In Episode 6 of TSC Talks Research 3.0, I finish up the discussion of CRISPR and TSC and the trajectory, I get into cannabis and the way they've deglimmered exploration of consciousness for those with rare diseases on hefty meds and how this relates to the cultivated biosphere that limits the full potential of the divine human. So many the templates for data and experimentation to build the current Healthcare 4.0 system and Precision Medicine. While many will be helped, there will be a dependence on the grid system.
YouTube Video: https://youtu.be/OqLKIZ7Q54s?si=8svWmKHp4ekiFOnR
Links: https://www.liebertpub.com/doi/10.1089/crispr.2024.0079 
https://pubmed.ncbi.nlm.nih.gov/39654514/ 
https://pediatricsnationwide.org/2024/01/11/innovative-gene-therapy-approach-for-treating-patients-with-tuberous-sclerosis-type-2/ https://pmc.ncbi.nlm.nih.gov/articles/PMC7793581/ 
https://innovativegenomics.org/news/crispr-clinical-trials-2026/ https://frontlinegenomics.com/sickle-cell-disease-a-2024-update/ epidiolexhcp.com 
nih.gov 
sciencedaily.com 
https://www.researchgate.net/publication/348347376_Gene_therapy_for_tuberous_sclerosis_complex_type_2_in_a_mouse_model_by_delivery_of_AAV9_encoding_a_condensed_form_of_tuberin globalgenes.org neurologylive.com berkeley.edu ccf.org

Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

In this episode I share information on the risks and side effects of CRISPR for individuals with TSC and in general as well as go into how those affected with TSC are "test bunnies" for much of this new technology, and my theories with documentation of why this is happening. I also go over some of the "no touch" technologies being rolled out and tested on those with diseases such as TSC where the nature of the genetics, a "monogenic" disorder, makes it a more suitable population to experiment on to gain information than other more common disorders, such as Alzheimer's, which involve 100s of genetic factors.  TSC population is kept in that "test bunny" role without ever addressing the external factors that make the disease more difficult to manage in the first place.

LINKS:
pmc.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
https://pmc.ncbi.nlm.nih.gov/articles/PMC7672342/
https://cdmrp.health.mil/tscrp/default
http://tuberous-sclerosis.org/research/tsa-funded-research/
https://www.mdpi.com/2075-1729/15/3/368
https://www.tscalliance.org/wp-content/uploads/2023/02/Training-Packet-Documents.pdf
https://pmc.ncbi.nlm.nih.gov/articles/PMC3010088/
https://pmc.ncbi.nlm.nih.gov/articles/PMC4527140/
https://pubmed.ncbi.nlm.nih.gov/19028034/
https://pmc.ncbi.nlm.nih.gov/articles/PMC6851053/
https://www.youtube.com/watch?v=hXRRq-dFuYg
https://www.youtube.com/watch?v=Hu2TvhhdEHY
https://www.youtube.com/watch?v=BFuXttZspaY
https://pmc.ncbi.nlm.nih.gov/articles/PMC5727703/
https://globalgenes.org/raredaily/transforming-tsc-epilepsy-with-a-precision-therapy/
https://pediatricsnationwide.org/2024/01/11/innovative-gene-therapy-approach-for-treating-patients-with-tuberous-sclerosis-type-2/
https://pmc.ncbi.nlm.nih.gov/articles/PMC3164024/
https://pmc.ncbi.nlm.nih.gov/articles/PMC11944049/
https://www.biorxiv.org/content/10.1101/2024.02.22.581652v1.full-text
https://pmc.ncbi.nlm.nih.gov/articles/PMC6408922/
https://www.mdpi.com/2076-3417/14/3/1132
https://pmc.ncbi.nlm.nih.gov/articles/PMC3744999/
https://www.researchgate.net/publication/24217930_Magnetically_Responsive_Nanoparticles_for_Drug_Delivery_Applications_Using_Low_Magnetic_Field_Strengths
https://pmc.ncbi.nlm.nih.gov/articles/PMC2933363/
https://pmc.ncbi.nlm.nih.gov/articles/PMC7998448/
https://pmc.ncbi.nlm.nih.gov/articles/PMC9230665/


Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

TSC Talks 3.0 Research, Episode 4
Here's my ongoing convo with AI delving into the funding behind rare disease research, non profits and how there are vested interests in continuing to bypass the full range of knowledge about what impacts the genome such as environmental (vaccines included) amplifications so they can justify the need for gene therapy via crispr, etchttps://rarediseases.org/about-us/financials-governance/
https://rarediseases.org/collection/nord-financials/
https://rarediseases.org/nord-releases-report-on-the-state-of-rare-disease-diagnosis-care-and-treatment-in-america-over-three-decades/
https://rarediseases.org/nord-state-report-card/
rarediseases.org
https://rarediseases.org/wp-content/uploads/2022/10/NORD_2020_Annual-Report_wFinancials.pdf
https://rarediseases.org/wp-content/uploads/2022/01/NORD_2020_Annual-Report_FINAL_SpreadView_web.pdf
https://rarediseases.org/wp-content/uploads/2022/10/NRD-1198-2019_Annual-Report_FNL_WebSize.pdf
https://www.eurordis.org/who-we-are/our-funding/
https://www.eurordis.org/who-we-are/projects-and-partnerships/
https://www.eurordis.org/partnerships/
https://www.eurordis.org/get-involved/join-the-eurordis-round-table-of-companies/
https://www.eurordis.org/publications/eurordis-policy-on-financial-support-by-commercial-companies-2/
https://www.eurordis.org/our-priorities/research/
https://www.eurordis.org/eurordis-supports-member-states-efforts-operating-grants-reintroduction/
https://www.eurordis.org/videos/rare-but-real-talking-rare-diseases-part-1-6/
download2.eurordis.org
vzacna-onemocneni.cz
https://everylifefoundation.org/rare-hub/rare-hub-partners-current-1-3/
https://everylifefoundation.org/financial-support/
https://everylifefoundation.org/everylifeeveryaction/
https://everylifefoundation.org/sitemap/
https://everylifefoundation.org/wp-content/uploads/2025/08/ELF-AnnualReport-2024-8.5x11-Proof-v6-081225.pdf
https://everylifefoundation.org/wp-content/uploads/2022/01/Guide-to-Patient-Involvement-FINAL-COMPLETE-GUIDE-Rev.pdf
https://everylifefoundation.org/wp-content/uploads/2016/05/Industry-Brochure-FINAL-May-2016.pdf


Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

Episode 3 of TSC Talks 3.0 Research
I drill down with the AI on the reality of what is happening in the rare disease expanse. The full expanse it's not explored we are jumping right into gene editing, like using whiteout, it isn't quite the same. It's a closed loop system. That is for sure.
links:
https://www.ninds.nih.gov/health-information/disorders/tuberous-sclerosis-complex#
https://pmc.ncbi.nlm.nih.gov/articles/PMC7672342/
https://www.ncbi.nlm.nih.gov/books/NBK1220/#
https://patienteducation.asgct.org/understanding-cell-gene-therapy/ethical-issues-germline-gene-editing#
https://pmc.ncbi.nlm.nih.gov/articles/PMC12103018/#
https://pubmed.ncbi.nlm.nih.gov/6873497/#
https://pmc.ncbi.nlm.nih.gov/articles/PMC6277505/#
https://www.researchgate.net/publication/326455213_Incidence_of_tuberous_sclerosis_and_age_at_first_diagnosis_new_data_and_emerging_trends_from_a_national_prospective_surveillance_study
https://pmc.ncbi.nlm.nih.gov/articles/PMC11944049/#
https://www.slu.edu/law/health/blog/2024/vence-bonham-dss.php#
https://tuberoussclerosiscenter.wustl.edu/about-tsc/causes/#
https://www.ncbi.nlm.nih.gov/books/NBK535878/#
https://pmc.ncbi.nlm.nih.gov/articles/PMC5524257/#
https://pmc.ncbi.nlm.nih.gov/articles/PMC5100696/#
https://link.springer.com/article/10.1007/s11569-025-00479-8#
https://www.ncbi.nlm.nih.gov/books/NBK535877/#
https://pmc.ncbi.nlm.nih.gov/articles/PMC11306935/#
https://pmc.ncbi.nlm.nih.gov/articles/PMC10338708/
https://www.thehastingscenter.org/genetic-therapies-for-rare-diseases-developing-ethical-regulatory-policies/#
https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/medical-ethics/education/high-school-bioethics-project/learning-scenarios/jesse-gelsinger-case
https://www.cliffsnotes.com/cliffs-questions/5224266#
https://www.bstquarterly.com/article/using-synthetic-biology-to-create-therapeutic-solutions/#
https://www.sciencedirect.com/science/article/pii/S1359644621001574
https://www.sciencedirect.com/science/article/abs/pii/S1359644621001574#

#raredisease #TuberousSclerosisComplex #GeneEditing

Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

​Episode 2 of ongoing research on Tuberous Sclerosis Complex based on the query~Is CRISPR CAS9 being researched to help/cure tuberous sclerosis?"
An exchange with Google AI mode in reference to the above query with the intention of making it clear the trajectory for those with rare diseases in terms of overriding our biological organic template and moving towards a more synthetic version. I picked up where I left off with Episode 1 and talk through Epigenetic "Switches", Gut-Brain Axis and Neuroinflammation, Why Researchers Are Skipping These Links, Potential Reasons for the Research Focus, Funding and Corporate Partnerships, Neuroinflammation Research, The "TAND" Project (TSC-Associated Neuropsychiatric Disorders), The PREVENT Trial, Basic Science and "Somatic Mosaicism", The "Funding Gap" regarding Conflicts of Interest, The Logic of the "Omission", Lived Experience vs. "Proven" Science,Why It Feels "Diabolical" & Finding the "Clean" Data https://www.mdpi.com/1422-0067/22/14/7273 https://pmc.ncbi.nlm.nih.gov/articles/PMC11275973/ https://www.ncbi.nlm.nih.gov/books/NBK206940/ https://www.nature.com/articles/s41398-024-02752-y https://clinicaltrials.gov/study/NCT01289912 https://pmc.ncbi.nlm.nih.gov/articles/PMC9253752/ https://www.intechopen.com/chapters/82669 https://pmc.ncbi.nlm.nih.gov/articles/PMC6748183/ https://pmc.ncbi.nlm.nih.gov/articles/PMC6278824/ https://www.nature.com/articles/s41439-022-00181-1 https://pmc.ncbi.nlm.nih.gov/articles/PMC3035853/ https://pmc.ncbi.nlm.nih.gov/articles/PMC5804531/ https://pubmed.ncbi.nlm.nih.gov/40558831/ https://docs.google.com/document/d/1ncDHvfDHkzVd1-H4Xgulz-mhSZxhwhydK6jWln90L5E/ (contact [email protected] for access)

Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

"Is CRISPR CAS9 being researched to help/cure tuberous sclerosis?" An exchange with Google AI mode in reference to the above query with the intention of making it clear the trajectory for those with rare diseases in terms of overriding our biological organic template and moving towards a more synthetic version. For many this will bring great relief as these rare diseases are challenging for affected and the ripple created in the realm. Instead of considering ALL the factors that have exacerbated and amplified rare diseases to the point of no return, our powers that be are forging ahead with gene therapy, at the germline. This disease is a data generator, and the affected population a perfect test template for gathering the intel needed , organ by organ to duplicate and integrate with the tech. No judgement, just sharing the conversation as I feel it's important to share these exchanges with the body of knowledge currently feeding the AI. https://youtu.be/lZKqFZWnp0c Here's a link to the queries. https://share.google/aimode/mwKaYPnKgzw54cs76












Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.